TOIIW (The Oncology Institute) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


TOIIW The Oncology Institute Inc TOIIW
56 GF Score
Price $0.06
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Other Stockholders Equity?

The Oncology Institute TOIIW 56 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review.

The Oncology Institute's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

The Oncology Institute's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil).

The Oncology Institute's annual Other Stockholders Equity declined from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) and declined from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil).

The Oncology Institute Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute Other Stockholders Equity Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 -0.00 -0.00 -0.00 -0.00

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
TOIIW
56GF Score
The Oncology Institute Inc TOIIW
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
The Oncology Institute (TOIIW) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on The Oncology Institute and its competitors.
Is The Oncology Institute's Other Stockholders Equity too high?
The Oncology Institute's current Other Stockholders Equity is $0.00 Mil. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Other Stockholders Equity compare to CCRN and SRTA?
The Oncology Institute's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Healthcare Providers & Services company?
A good Other Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on The Oncology Institute and its competitors. The Oncology Institute's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Oncology Institute Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOIIW

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price